GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bionomics Ltd (NAS:BNOX) » Definitions » Total Liabilities

Bionomics (Bionomics) Total Liabilities : $6.57 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bionomics Total Liabilities?

Bionomics's Total Liabilities for the quarter that ended in Dec. 2023 was $6.57 Mil.

Bionomics's quarterly Total Liabilities increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($6.62 Mil) but then declined from Jun. 2023 ($6.62 Mil) to Dec. 2023 ($6.57 Mil).

Bionomics's annual Total Liabilities increased from Jun. 2021 ($5.10 Mil) to Jun. 2022 ($5.90 Mil) and increased from Jun. 2022 ($5.90 Mil) to Jun. 2023 ($6.62 Mil).


Bionomics Total Liabilities Historical Data

The historical data trend for Bionomics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bionomics Total Liabilities Chart

Bionomics Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.97 15.03 5.10 5.90 6.62

Bionomics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.80 - 6.62 6.57

Bionomics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bionomics's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.771+(0.243+2.475
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.111+0.015)
=6.62

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=28.862-22.247
=6.62

Bionomics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.961+(0.182+2.414
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+1.015+0)
=6.57

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=26.006-19.433
=6.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bionomics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bionomics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Bionomics (Bionomics) Business Description

Traded in Other Exchanges
Address
200 Greenhill Road, Eastwood, SA, AUS, 5063
Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

Bionomics (Bionomics) Headlines